Drug Profile


Alternative Names: APD 334

Latest Information Update: 10 May 2016

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis

Most Recent Events

  • 30 Mar 2016 Arena Pharmaceuticals has patent protection for APD 334 in USA, Japan, China, Australia and Russia
  • 30 Mar 2016 Arena Pharmaceuticals has patents pending for APD 334 in six jurisdiction, including Europe, Brazil, Canada, India and South Korea (Arena Pharmaceuticals 10-K; March 2016)
  • 02 Sep 2015 Arena Pharmaceuticals plans a phase II extension trial for Ulcerative colitis in USA (NCT02536404)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top